Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 112,375
  • Shares Outstanding, K 75,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,752 K
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.89
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings $-0.09 on N/A
  • Next Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.43 +4.20%
on 04/25/24
1.74 -14.37%
on 05/09/24
+0.02 (+1.36%)
since 04/24/24
3-Month
1.22 +22.13%
on 03/04/24
1.75 -14.86%
on 04/04/24
+0.14 (+10.37%)
since 02/23/24
52-Week
1.20 +24.17%
on 02/07/24
4.49 -66.82%
on 06/23/23
-1.37 (-47.90%)
since 05/24/23

Most Recent Stories

More News
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
MRK : 129.49 (-1.22%)
RHHBY : 31.6000 (-0.60%)
AMGN : 305.84 (-0.22%)
BNTX : 96.95 (-2.07%)
Stocks in play: Oncolytics Biotech® Inc.

Presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One ...

ONC.TO : 1.49 (+2.76%)
Stocks in play: Oncolytics Biotech Inc

Announces ASCO Abstracts highlight Pelareorep's potential in pancreatic icancer and immunotherapeutic ...

ONC.TO : 1.49 (+2.76%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
RENB : 1.4200 (+7.58%)
CYTO : 1.7800 (+4.09%)
PFE : 28.88 (+0.66%)
ABBV : 157.06 (-0.76%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
RENB : 1.4200 (+7.58%)
CYTO : 1.7800 (+4.09%)
PFE : 28.88 (+0.66%)
ABBV : 157.06 (-0.76%)
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Trial-in-progress abstract highlights new cohort that could expand the company’s pancreatic cancer program   Pelareorep’s ability to expand TILs highlights its immunotherapeutic mechanism of action...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 1.0900 (+2.83%)
CADL : 7.80 (-27.03%)
AZN : 78.54 (+0.46%)
MRUS : 59.99 (+36.12%)
LTRN : 6.27 (+0.64%)
ONC.TO : 1.49 (+2.76%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
CADL : 7.80 (-27.03%)
AZN : 78.54 (+0.46%)
MRUS : 59.99 (+36.12%)
LTRN : 6.27 (+0.64%)
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.49 (+2.76%)
RHHBY : 31.6000 (-0.60%)
MRUS : 59.99 (+36.12%)
MGNX : 4.55 (-1.73%)
IMRX : 1.3900 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the...

See More

Key Turning Points

3rd Resistance Point 1.59
2nd Resistance Point 1.56
1st Resistance Point 1.52
Last Price 1.49
1st Support Level 1.45
2nd Support Level 1.42
3rd Support Level 1.38

See More

52-Week High 4.49
Fibonacci 61.8% 3.23
Fibonacci 50% 2.84
Fibonacci 38.2% 2.46
Last Price 1.49
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar